Premium
Interleukin‐2‐lnduced splenic enlargement
Author(s) -
Pozniak Myron A.,
Christy Paul S.,
Albertini Mark R.,
Duffek Susan M.,
Schiller Joan H.
Publication year - 1995
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19950601)75:11<2737::aid-cncr2820751117>3.0.co;2-a
Subject(s) - medicine
Background . Splenomegaly in patients with cancer raises the suspicion of tumor involvement. Splenic enlargement in the absence of splenic metastases, however, has been reported in patients treated with interleukin‐2 (IL‐2) immunotherapy. This study characterizes the change in spleen size that occurred in 42 patients treated with IL‐2 between 1989 and 1993 for nonhematologic malignancies. Methods . Computed tomography (CT) scans before and during immunotherapy were available for review on all 42 patients and after immunotherapy on 16 of these patients. The splenic index was measured for each CT by a single reader blinded to the time course of IL‐2 therapy. Results . Mean splenic index increased 64.1% from 646 cm 3 (standard deviation [SD], 387) pre‐IL‐2 to 1059 cm 3 (SD, 534) during therapy with IL‐2 (P < 0.0001). The splenic index remained elevated at 1112 cm 3 (SD, 633) after completion of IL‐2 therapy. Conclusions . Splenomegaly, temporally associated with IL‐2 therapy for nonhematologic malignancies, is likely to represent a sequela of therapy and not tumor progression. Cancer 1995;75:2737–41.